Intra-Cellular Therapies Inc.

NAS: ITCI

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Intra-Cellular Therapies Inc.

After Hours

ITCI

/zigman2/quotes/209441868/composite

60.00

Change

+2.10 +3.63%

Volume

Volume 30,591

Jun 27, 2022, 6:12 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/209441868/composite

Today's close

$ 55.62

$ 57.90

Change

+2.28 +4.10%

Day low

Day high

$55.97

$59.04

Open: 56.20

52 week low

52 week high

$28.40

$66.00

Market cap

$5.25B

Average volume

872,018

P/E ratio

N/A

Rev. per Employee

$163,678

EPS

-3.62

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:

Indexes

Dow(INDU) INDU
Nasdaq (COMP) COMP
S&P 500 (SPX) SPX
Global Dow (GDOW) GDOW

/news/latest/company/us/itci

MarketWatch News on ITCI

Intra-Cellular Therapies started at buy with $75 stock price target at UBS

10:52 a.m. June 14, 2022

- Tomi Kilgore
12 biotech stocks to consider buying now as prospects for the sector brighten this year

10:01 a.m. Feb. 7, 2022

- Michael Brush
The FDA Is About to Make Some Major Drug Decisions

2:51 p.m. Oct. 16, 2021

- Barron's Online
Intra-Cellular says clinical study shows its schizophrenia drug helps patients with bipolar disorder

9:19 a.m. Sept. 27, 2021

- Jaimy Lee
Intra-Cellular Therapies downgraded to neutral from overweight at J.P. Morgan

8:54 a.m. Jan. 31, 2020

- Tomi Kilgore
Intra-Cellular Therapies stock price target raised to $65 vs. $29 at Canaccord

11:48 a.m. Dec. 24, 2019

- Ciara Linnane
Intra-Cellular Therapies reiterated as buy at Canaccord

11:48 a.m. Dec. 24, 2019

- Ciara Linnane
Investors flock to neuro drug makers after FDA approves new schizophrenia drug

8:06 a.m. Dec. 24, 2019

- Jaimy Lee
UPDATE: Intra-Cellular Therapies stock soars 83% premarket after FDA approves schizophrenia treatment

8:59 a.m. Dec. 23, 2019

- Ciara Linnane
Intra-Cellular Therapies gets FDA approval for schizophrenia treatment

8:14 a.m. Dec. 23, 2019

- Ciara Linnane
Intra-Cellular Therapies stock soars 42% premarket

8:14 a.m. Dec. 23, 2019

- Ciara Linnane
Intra-Cellular Therapies stock down 15% after disappointing Phase 3 trial results

8:58 a.m. July 8, 2019

- Sarah Toy
Intra-Cellular Therapies shares slide 7% after resuming trade following halt.

7:36 a.m. July 8, 2019

- Ciara Linnane
Intra-Cellular announces positive results in late-stage trials of treatment for bipolar depression

7:14 a.m. July 8, 2019

- Ciara Linnane
Intra-Cellular announces positive results in late-stage trial of treatment for bipolar depression

7:05 a.m. July 8, 2019

- Ciara Linnane
Intra-Cellular Therapies and Sol-Gel Technologies halted for news pending

6:58 a.m. July 8, 2019

- Ciara Linnane
Intra-Cellular Therapies stock down 22% after discontinuation of Phase 3 trial

9:52 a.m. Dec. 18, 2018

- Sarah Toy
Tech jobs are barely a blip on this map of the best-paying companies in each state

8:34 a.m. July 5, 2018

- Shawn Langlois
Intra-Cellular Therapies started at overweight with $25 stock price target at J.P. Morgan

8:59 a.m. Feb. 26, 2018

- Tomi Kilgore
Intra-Cellular Therapies upgraded to buy from hold at SunTrust RH

9:30 a.m. Nov. 9, 2017

- Tomi Kilgore
Loading more headlines...